- The collaboration brings together LEO Pharma’s “expertise” in medical dermatology and DEBRA Research’s pharmaceutical experience to develop novel medicines for this condition. DEBRA Research managing director Prof Hubert Truebel The post...
- Concurrently, the company also secured a funding of $27m in Series B round. The proceeds are set to be utilised for progressing the therapy through a Phase I The post FDA clears Auron’s AUTX-703 IND to treat haematological...
- The acquisition primarily comprises cash payments, with a smaller portion in the form of BioNTech American Depositary Shares. In addition, there are potential performance-based payments of up to The post BioNTech concludes acquisition of...
- The decision is based on outcomes from the Phase III CheckMate -9DW trial. According to the outcomes of the trial presented by the company in June last year, The post EMA’s CHMP recommends approval of Bristol Myers Squibb’s HCC treatment...
- Additionally, the company is on track to submit a marketing authorisation application (MAA) to the European Medicines Agency (EMA) in the first quarter of this year. The Division The post Scholar Rock submits application of SMA therapy...
- Sanofi Ventures and EQT Life Sciences jointly led the funding round. New investors like Novartis Venture Fund, RiverVest Venture Partners, Mirae Asset Financial Group, abrdn-managed funds, GHR Foundation, The post Atalanta Therapeutics...
- This places the company’s valuation at $525m. Transformation Capital led the funding round, with participation from current investors like World Innovation Lab, OCV Partners, UP2398, Khosla Ventures, Cone The post Rad AI raises $60m to...
- Antibiotic resistance is a global public health crisis responsible for more than a million deaths annually. By 2050, the World Health Organization estimates it could surpass cancer and heart disease as the leading cause of death as more...
- Biomedical engineers at Duke University have developed an AI-based platform that designs short proteins, termed peptides, capable of binding and destroying previously undruggable disease-causing proteins. Inspired by OpenAI’s image...
- A natural compound derived from gut-friendly bacteria significantly slows the progression of vitiligo and may restore pigmentation, reports a new Northwestern University pre-clinical study in mice. The findings could offer hope to...
- Utilising its collaboration with Microsoft and a team of multidisciplinary scientists, the company is poised to disrupt the conventional therapeutic discovery model. The company was co-founded by Dr The post Manas AI launches to focus on...
- The application is currently being evaluated by the EMA’s Committee for Medicinal Products for Human Use (CHMP). Mavorixafor would become the first drug for this syndrome in the European The post EMA validates X4’s mavorixafor...
- Basal cell carcinomas, the most common form of skin cancer, occur in chronically sun-exposed areas such as the face. Locally advanced tumours in particular can be difficult to treat surgically. A research team from MedUni Vienna and...
- A collaborative study between researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), and the Institute for Biostatistics and Informatics in Medicine and Ageing Research, Rostock University...
- Memantine/donepezil 14-10 mg and 28-10 mg capsules are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. This product, referencing NAMZARIC of AbbVie, has The post FDA approves Amneal...
- A team of scientists has developed a groundbreaking approach using specially designed peptides to improve drug formulations. This innovative method significantly enhances anti-tumor efficacy, as demonstrated in leukemia models. The...
- As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch of one of the largest surveys examining global public...
- Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes, heart disease or...
- Researchers at Karolinska Institutet and the Astrid Lindgren Children's Hospital in Sweden have determined how children's immune systems react to different kinds of cancer depending on their age. The study, which is published in the...
- Antibiotic overuse is a key driver in the rise of antimicrobial resistance (AMR), a major global health crisis. Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Duke-NUS Medical...
- Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast...
- A new study in Nature by last year's Nobel Laureate in Chemistry reveals a possible game-changer in snakebite treatment. Researchers have created new proteins that neutralise lethal toxins found in snake venom, potentially offering a...
- With antibiotic resistance a growing problem, University of Virginia School of Medicine researchers have developed cutting-edge computer models that could give the disease-fighting drugs a laser-like precision to target only specific...
- Scientists at the University of Stuttgart have succeeded in controlling the structure and function of biological membranes with the help of "DNA origami". The system they developed may facilitate the transportation of large therapeutic...
- Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust immune system CAR-Ts (chimeric antigen...
- Researchers from POSTECH and Kyungpook National University have developed a novel inhalable therapeutic delivery system for lung cancer, leveraging mucoadhesive protein nanoparticles inspired by the adhesive properties of marine mussels....
- Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular dystrophy with the help of gene-editing. Preclinical research led by the Spuler Lab published in Nature...
- A varied diet rich in vegetables is known to be healthy for one's well-being. Excessive consumption of meat, especially red meat, can lead to chronic and cardiovascular diseases. That is also because what we eat shapes the gut...
- A new study from researchers at the Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy at Tufts University, which published in Nature Medicine on January 6, estimates that 2.2 million new cases of type 2 diabetes...
- Introducing Annotatability - a powerful new framework to address a major challenge in biological research by examining how artificial neural networks learn to label genomic data. Genomic datasets often contain vast amounts of annotated...
- The inflammatory disease affects around one in 2,000 people in the US
- Results from a mid-stage of the candidate were recently published in the NEJM
- The skin disease affects an estimated 1% of the population in most studied countries
- The collaboration will first focus on developing products for long COVID and ME/CFS
- Researchers used a technique to identify specific molecular details of biotin-labelled proteins
- Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year
- The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals
- The drug could prevent conditions including diabetic eye and kidney disease in diabetes
- The Yellow Card Biobank will begin investigating direct oral anticoagulants such as apixaban
- The deal gives the company access to a candidate being evaluated in primary biliary cholangitis
- There are now more than 8,000 patients who are potentially eligible for treatment with Casgevy
- Approximately one in 10,000 people are affected by the genetic blood clotting disorder
- The rare genetic disorder is estimated to affect around one in every 40,000 people in the UK
- F404 mutations combined with pre-existing mutations caused resistance to fulvestrant
- Both companies will leverage their autologous CAR-T cell therapy programmes
- Ten23 health expands former swissfillon facility in Visp, Switzerland jkeenan Mon, 03/28/2022 - 08:41
- Sobi to trim staff as Pfizer manufacturing contract ends early jkeenan Thu, 03/24/2022 - 08:40
- Epinephrine recall: Adamis pulls Symjepi injections for needle clogging risks aliu Wed, 03/23/2022 - 11:18
- Fujifilm makes yet another deal to jack up cell and gene therapy capacity kdunleavy Tue, 03/22/2022 - 21:13
- Takeda's Natpara relaunch bid falls flat as manufacturing concerns drag on jkeenan Tue, 03/22/2022 - 09:22